CITE clinical guidance documents provide healthcare professionals with evidence-based recommendations for the management of relapsed/refractory multiple myeloma. These guidance documents are developed by an expert panel of clinicians who evaluate the available literature and develop consensus-based recommendations based on the best available evidence.

Multiple myeloma is an aggressive cancer characterized by the proliferation of abnormal clonal plasma cells, typically affecting adult patients ≥65 years old. Complications include anemia, bone damage, increased susceptibility to infections, and progressive immune and kidney dysfunction. Almost all patients with multiple eventually relapse, with the time interval of sustained remission decreasing with each line of therapy. In the relapsed/refractory setting (RRMM), multiple myeloma is associated with a poor prognosis. After failure of three classes of therapies (proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies), patients on subsequent treatment regimens show a median overall survival of 9.3 months. Moreover, some patients do not achieve a durable, or any, response to treatment, further demonstrating a need for effective therapeutic options in the RRMM population.